# Efimosfermin PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/efimosfermin

> The next catalyst for efimosfermin, sponsored by GSK plc (GSK), is its topline data readout, Jul to Oct 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | efimosfermin |
| Codes | BOS-580 |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [Metabolic Dysfunction-Associated Steatohepatitis](https://sec-api.dev/indications/metabolic-dysfunction-associated-steatohepatitis), [Nonalcoholic Steatohepatitis (NASH)](https://sec-api.dev/indications/nonalcoholic-steatohepatitis-nash) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### October 27, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Nonalcoholic Steatohepatitis (NASH).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04880031 (A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-27 (ACTUAL); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT04880031

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Metabolic Dysfunction-Associated Steatohepatitis; Non-alcoholic Fatty Liver Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06920043 (A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-03 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06920043

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Metabolic Dysfunction-Associated Steatohepatitis; Non-alcoholic Fatty Liver Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06920043 (A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-03 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06920043

## Same indication

- [Adi-peg20](https://sec-api.dev/pdufa/adi-peg20) (PII)
- [Aln-cideb](https://sec-api.dev/pdufa/aln-cideb) (REGN)
- [Aro-inhbe](https://sec-api.dev/pdufa/aro-inhbe) (ARWR)
- [Miricorilant (cohort a)](https://sec-api.dev/pdufa/miricorilant-cohort-a) (CORT)
- [Rencofilstat](https://sec-api.dev/pdufa/rencofilstat) (HEPA)

Calendar months: [July 2028](https://sec-api.dev/fda-calendar/2028-07)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/efimosfermin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Efimosfermin PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/efimosfermin

```bibtex
@misc{secapidev_pdufa_efimosfermin_20261116,
  title        = {Efimosfermin PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/efimosfermin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_efimosfermin_20261116","title":"Efimosfermin PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/efimosfermin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
